The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Boyko A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain and Neurotechnologies

Melnikov M.V.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of FMBA;
Institute of Immunology of FMBA

Kozin M.S.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of FMBA;
National Medical Research Center of Cardiology

Kulakova O.G.

Pirogov Russian National Research Medical University

The role of mitochondria in pathological mechanisms of innate immunity in multiple

Authors:

Boyko A.N., Melnikov M.V., Kozin M.S., Kulakova O.G.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(7‑2): 32‑37

DOI: 10.17116/jnevro202012007232

Read: 2852 times

Download PDF (RU)
Contact the author
Table of contents

THE ROLE OF MITOCHONDRIA IN PATHOLOGICAL MECHANISMS OF INNATE IMMUNITY IN MULTIPLE
THE ROLE OF MITOCHONDRIA IN PATHOLOGICAL MECHANISMS OF INNATE IMMUNITY IN MULTIPLE

To cite this article:

Boyko AN, Melnikov MV, Kozin MS, Kulakova OG. The role of mitochondria in pathological mechanisms of innate immunity in multiple. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(7‑2):32‑37. (In Russ.)
https://doi.org/10.17116/jnevro202012007232

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
A comprehensive study of Alzheimer’s disease biomarkers in plasma and cere­brospinal fluid. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):43-53
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Mole­cular mechanisms of acute disseminated ence­phalomyelitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):7-11
The role of mono­cytes in the immu­nopathogenesis of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):23-27
Resu­lts of a 5-year project for the early diagnosis of multiple scle­rosis in first-line blood rela­tives (RADIRS program). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):28-33
Current epidemiology of MS with onset in childhood and adolescence (pediatric multiple scle­rosis). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):34-38
Features of the clinical course of multiple scle­rosis as a factor in persistent disa­bility. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):39-44
Comparing the effi­cacy of divo­zilimab and second-line treatments for rela­psing-remitting multiple scle­rosis in the Russian Fede­ration: a systematic review and network meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):58-68
A clinical case of X-linked adre­noleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107
Arti­ficial inte­lligence capa­bilities in multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):14-21
Abstract:

The review discusses the role of mitochondria in multiple sclerosis (MS). Previously, damage to the mitochondria was regarded as a manifestation of secondary damage to axons and neurons, i.e. as a marker of neurodenegation. Recently, the role of mitochondria in the early stages of MS development, when they could participate in the activation of innate immunity and trigger activation of autoimmune responses of acquired immunity, has been increasingly discussed. The role of polymorphism mitochondrial DNA changes in MS is discussed.

Keywords:

multiple sclerosis
mitochondria
neurodegeneration
mitochondrial DNA
innative immunity

Authors:

Boyko A.N.

Pirogov Russian National Research Medical University;
Federal Center of Brain and Neurotechnologies

Melnikov M.V.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of FMBA;
Institute of Immunology of FMBA

Kozin M.S.

Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of FMBA;
National Medical Research Center of Cardiology

Kulakova O.G.

Pirogov Russian National Research Medical University

Received:

14.05.2020

Accepted:

16.05.2020

Close metadata

References:

  1. Veit Rothhammer V, Quintana FJ. Environmental control of autoimmune inflammation in the central nervous system. Curr Opin Immunol. 2016;43:46-53.  https://doi.org/10.1016/j.coi.2016.09.002
  2. Boyko A, Kobelt G, Berg J, Boyko O, Popova E, Capsa D, Eriksson J. The European Multiple Sclerosis Platform. New insights into the burden and costs of multiple sclerosis in Europe: Results for Russia. Mult Sler. 2017;23(2):155-165.  https://doi.org/10.1177/1352458517708668
  3. Boyko AN, Favorova OO. Multiple sclerosis: molecular and cell mechanisms (a review). Molecular Biology. 1995;29(4):727-749.(In Russ.).
  4. Gharagozloo M, Gris KV, Mahvelati T, Amrani A, Lukens JR, Gris D. NLR-Dependent Regulation of Inflammation in Multiple Sclerosis. Front Immunol. 2017;8:2012. https://doi.org/10.3389/fimmu.2017.02012
  5. Stys PK, Zamponi GW, van Minnen J, Geurts JJ. Will the real multiple sclerosis please stand up? Nat Rev Neurosci. 2012;13(7):507-514.  https://doi.org/10.1038/nrn3275
  6. Gusev EI, Boyko AN. Multiple sclerosis: achievements of the decade]. Zh Nevrol Psikhiatr im S.S. Korsakova. 2007;107(4. Vyp. 2 Rasseiannyi scleros):4-13. (In Russ.).
  7. Kannan V, Kiani NA, Piehl F, Tegner J. A minimal unified model of disease trajectories captures hallmarks of multiple sclerosis. Math Biosci. 2017;289:1-8.  https://doi.org/10.1016/j.mbs.2017.03.006
  8. Klotz L, Havla J, Schwab N, Hohlfeld R, Barnett M, Reddel S, Wiendl H. Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. Ther Adv Neurol Disord. 2019;12:1756286419836571. https://doi.org/10.1177/1756286419836571
  9. Boyko AN. Cancers and multiple sclerosis: risk of comorbidity and influence of disease modifying therapy. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2019;119(2. Vyp. 2):86-93. (In Russ.). https://doi.org/10.17116/jnevro20191192286
  10. Warnke C, Leussink VI, Goebels N, Aktas O, Boyko A, Kieseier BC, Hartung HP. Cladribine as a therapeutic option in multiple sclerosis. Clin Immunol. 2012;142(1):68-75.  https://doi.org/10.1016/j.clim.2011.05.009
  11. Ingwersen J, Aktas O, Kuery P, Kieseier B, Boyko A, Hartung HP. Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy. Clin Immunol. 2012;142(1):15-24.  https://doi.org/10.1016/j.clim.2011.10.008
  12. Briard E, Rudolph B, Desrayaud S, Krauser JA, Auberson YP. MS565: A SPECT Tracer for Evaluating the Brain Penetration of BAF312 (Siponimod). ChemMedChem. 2015;10(6):1008-1018. https://doi.org/10.1002/cmdc.201500115
  13. Gentile A, Musella A, Bullitta S, Fresegna D, De Vito F, Fantozzi R, Piras E, Gargano F, Borsellino G, Battistini L, Schubart A, Mandolesi G, Centonze D. Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis. J Neuroinflammation. 2016;13(1):207.  https://doi.org/10.1186/s12974-016-0686-4
  14. Leist TP, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol. 2011;34(1):28-35.  https://doi.org/10.1097/WNF.0b013e318204cd90
  15. Boyko AN, Boyko OV. Cladribine tablets’ potential role as a key example of selective immune reconstitution therapy in multiple sclerosis. Degener Neurol Neuromuscul Dis. 2018;8:35-44.  https://doi.org/10.2147/DNND.S161450
  16. Kozin MS, Kulakova OG, Favoroa OO. Involvement of Mitochondria in Neurodegeneration in Multiple Sclerosis. Biochemistry. 2018;83(7):813-830.  https://doi.org/10.1134/S0006297918070052
  17. Huang Y, Halliday GM. Aspects of innate immunity and Parkinson’s disease. Front Pharmacol. 2012;3:33.  https://doi.org/10.3389/fphar.2012.00033
  18. McGuire PJ. Mitochondrial dysfunction and the aging immune system. Biology (Basel). 2019;8(2):26.  https://doi.org/10.3390/biology8020026
  19. Pacella I, Piconese S. Immunometabolic checkpoints of Treg dynamics: adaptation to microenvironmental opportunities and challenges. Front Immunol. 2019;10:1889. https://doi.org/10.3389/fimmu.2019.01889
  20. Sigal DS, Miller HJ, Schram ED, Saven A. Beyond hairy cell: the activity of cladribine in other hematologic malignancies. Blood. 2010;116(16):2884-2296. https://doi.org/10.1182/blood-2010-02-246140
  21. Baulina N, Kulakova O, Kiselev I, Osmak G, Popova E, Boyko A, Favorova O. Immune-related miRNA expression patterns in peripheral blood mononuclear cells differ in multiple sclerosis relapse and remission. J Neuroimmunol. 2018;317:67-76.  https://doi.org/10.1016/j.jneuroim.2018.01.005
  22. Kulakova OG, Kabilov MR, Danilova LV, Popova EV, Baturina OA, Tsareva EY, Baulina NM, Kiselev IS, Boyko AN, Favorov AV, Favorova OO, Vlassov VV. Whole-genome DNA methylation analysis of peripheral blood mononuclear cells in multiple sclerosis patients with different disease courses. Acta Naturae. 2016;8(3):103-110. 
  23. Veit Rothhammer V, Quintana FJ. Environmental control of autoimmune inflammation in the central nervous system. Curr Opin Immunol. 2016;43:46-53. 
  24. Campbell GR, Ziabreva I, Reeve AK, Reynolds R, Turnbull DM, Mahad DJ. Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann Neurol. 2011;69:481-492.  https://doi.org/10.1002/ana.22109
  25. Mahad DJ, Ziabreva I, Campbell G, Lax N, White K, Hanson PS, Lassmann H, Turnbull DM. Mitochondrial changes within axons in multiple sclerosis. Brain. 2009;132(Pt 5):1161-1174. https://doi.org/10.1007/s00401-010-0710-1
  26. van Horssen J, Witte ME, Ciccarelli O. The role of mitochondria in axonal degeneration and tissue repair in MS. Mult Scler. 2012;18(8):1058-1067. https://doi.org/10.3390/ijms161023463
  27. Witte ME, Mahad DJ, Lassmann H, van Horssen J. Mitochondrial dysfunction contributes to neurodegeneration in multiple sclerosis. Trends Mol Med. 2014;20(3):179-187.  https://doi.org/10.1016/j.molmed.2013.11.007
  28. Kazantseva IA, Kotov SV, Borodataya EV, Sidorova OP, Borodin AV. Mitochondrial disorders in multiple sclerosis. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2018;118(8/2):5-9. (In Russ.). https://doi.org/10.17116/jnevro20181180825
  29. Varhaug KN, Vedeler CA, Myhr KM Aarseth JH, Tzoulis C, Bindoff LA. Increased levels of cell-free mitochondrial DNA in the cerebrospinal fluid of patients with multiple sclerosis. Mitochondrion. 2017;34:32-35.  https://doi.org/10.1016/j.mito.2016.12.003
  30. Lowes H, Pyle A, Duddy M, Hudson G. Cell-free mitochondrial DNA in progressive multiple sclerosis. Mitochondrion. 2019;46:307-312.  https://doi.org/10.1016/j.mito.2018.07.008
  31. DeBalsi KL, Hoff KE, Copeland WC. Role of the mitochondrial DNA replication machinery in mitochondrial DNA mutagenesis, aging and age-related diseases. Ageing Res Rev. 2017;33:89-104. 
  32. Zambonin JL, Zhao C, Ohno N, Campbell GR, Engeham S, Ziabreva I, Schwarz N, Lee SE, Frischer JM, Turnbull DM, Trapp BD, Lassmann H, Franklin RJ, Mahad DJ. Increased mitochondrial content in remyelinated axons: implications for multiple sclerosis. Brain. 2011;134(7):1901-1913. https://doi.org/10.1093/brain/aww205
  33. Huang Y, Halliday GM. Aspects of innate immunity and Parkinson’s disease. Front Pharmacol. 2012;3:33.  https://doi.org/10.3389/fphar.2012.00033
  34. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140(6):805-820.  https://doi.org/10.1016/j.cell.2010.01.022
  35. Paludan SR, Bowie AG. Immune sensing of DNA. Immunity. 2013;38(5):870-880.  https://doi.org/10.1016/j.immuni.2013.05.004
  36. Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. Nat Immunol. 2015;16(4):343-353.  https://doi.org/10.1038/ni.3123
  37. Mills EL, Kelly B, O’Neill LAJ. Mitochondria are the powerhouses of immunity. Nat Immunol. 2017;18(5):488-498.  https://doi.org/10.1038/ni.3704
  38. West AP. Mitochondrial dysfunction as a trigger of innate immune responses and inflammation. Toxicology. 2017;391:54-63.  https://doi.org/10.1016/j.tox.2017.07.016
  39. Gambardella S, Limanaqi F, Ferese R, Biagioni F, Campopiano R, Centonze D, Fornai F. ccf-mtDNA as a Potential Link Between the Brain and Immune System in Neuro-Immunological Disorders. Front Immunol. 2019;10:1064. https://doi.org/10.3389/fimmu.2019.01064
  40. Varhaug KN, Vedeler CA, Myhr KM, Aarseth JH, Tzoulis C, Bindoff LA. Increased levels of cell-free mitochondrial DNA in the cerebrospinal fluid of patients with multiple sclerosis. Mitochondrion. 2017;34:32-35.  https://doi.org/10.1016/j.mito.2016.12.003
  41. Leurs CE, Podlesniy P, Trullas R, Balk L, Steenwijk MD, Malekzadeh A, Piehl F, Uitdehaag BM, Killestein J, van Horssen J, Teunissen CE. Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment. Mult Scler. 2018;24(4):472-480.  https://doi.org/10.1177/1352458517699874
  42. Mehta SR, Pérez-Santiago J, Hulgan T, Day TR, Barnholtz-Sloan J, Gittleman H, Letendre S, Ellis R, Heaton R, Patton S, Suben JD, Franklin D, Rosario D, Clifford DB, Collier AC, Marra CM, Gelman BB, McArthur J, McCutchan A, Morgello S, Simpson D, Connor J, Grant I, Kallianpur A. Cerebrospinal fluid cell-free mitochondrial DNA is associated with HIV replication, iron transport, and mild HIV-associated neurocognitive impairment. J Neuroinflammation. 2017;14(1):72.  https://doi.org/10.1186/s12974-017-0848-z
  43. IMSGC. Multiple Sclerosis Genomic Map Implicates Peripheral Immune Cells and Microglia in Susceptibility. Science. 2019;365(6460):eaav7188. https://doi.org/10.1126/science.aav7188
  44. Yao L, Xu Z, Wan L. Whole mitochondrial DNA sequencing analysis in 47 Han populations in Southwest China. Med Sci Monit. 2019;25:6482-6490. https://doi.org/10.12659/MSM.916275
  45. Bereiter-Hahn J. Mitochondrial dynamics in aging and disease. Prog Mol Biology Trans Sci. 2014;127:93-131.  https://doi.org/10.1016/B978-0-12-394625-6.00004-0
  46. Pakendorf B, Stoneking M. Mitochondrial DNA and human evolution, Annu Rev Genomics Hum. Genet. 2005;6:165-183. 
  47. Hassani-Kumleh H, Houshmand M, Panahi MS, Riazi GH, Sanati MH, Gharagozli K, Ghabaee M. Mitochondrial D-loop variation in Persian multiple sclerosis patients: K and A haplogroups as a risk factor. Cell Mol. Neurobiol. 2006;26:119-125. 
  48. Houshmand M, Sanati MH, Babrzadeh F, Ardalan A, Teimori M, Vakilian M, Akuchekian M, Farhud D, Lotfi J. Population screening for association of mitochondrial haplogroups BM, J, K and M with multiple sclerosis: interrelation between haplogroup J and MS in Persian patients. Mult Scler. 2005;11:728-730. 
  49. Vyshkina T, Sylvester A, Sadiq S, Bonilla E, Canter JA, Perl A, Kalman B. Association of common mitochondrial DNA variants with multiple sclerosis and systemic lupus erythematosus. Clin Immunol. 2008;129:31-35.  https://doi.org/10.1016/j.clim.2008.07.011
  50. Yu X, Koczan D, Sulonen AM, Akkad DA, Kroner A, Comabella M, Costa G, Corongiu D, Goertsches R, Camina-Tato M, Thiesen HJ, Nyland HI, Mørk SJ, Montalban X, Rieckmann P, Marrosu MG, Myhr KM, Epplen JT, Saarela J, Ibrahim SM.mtDNA nt13708A variant increases the risk of multiple sclerosis. PLoS One. 2008;3:e1530. https://doi.org/10.1371/journal.pone.0001530
  51. Tranah GJ, Santaniello A, Caillier SJ, D’Alfonso S, Martinelli Boneschi F, Hauser SL, Oksenberg JR. Mitochondrial DNA sequence variation in multiple sclerosis. Neurology. 2015;85:325-330.  https://doi.org/10.1212/WNL.0000000000001744
  52. Kozin MS, Kulakova OG, Kiselev IS, Balanovsky OP, Boyko AN, Favorova OO. Variants of Mitochondrial Genome and Risk of Multiple Sclerosis Development in Russians. Acta Naturae. 2018;10(4):79-86. (In Russ.).
  53. Otaegui D, Sáenz A, Martínez-Zabaleta M, Villoslada P, Fernández-Manchola I, Alvarez de Arcaya A, Emparanza JI, López de Munain A. Mitochondrial haplogroups in Basque multiple sclerosis patients. Mult Scler. 2004;10:532-535. 
  54. Mihailova SM, Ivanova MI, Quin LM, Naumova EJ. Mitochondrial DNA variants in Bulgarian patients affected by multiple sclerosis. Eur J Neurol. 2007;14:44-47. 
  55. Hudson G, Gomez-Duran A, Wilson IJ, Chinnery PF. Recent mitochondrial DNA mutations increase the risk of developing common late-onset human diseases. PLoS Genet. 2014;10:e1004369. https://doi.org/10.1371/journal.pgen.1004369
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.